{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:47:48Z","timestamp":1754261268839},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T00:00:00Z","timestamp":1340236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11255-012-0220-2","type":"journal-article","created":{"date-parts":[[2012,8,13]],"date-time":"2012-08-13T21:10:05Z","timestamp":1344892205000},"page":"1681-1689","source":"Crossref","is-referenced-by-count":7,"title":["The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"May","family":"Al-Maghrebi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elijah O.","family":"Kehinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehoram T.","family":"Anim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehraj","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,21]]},"reference":[{"key":"220_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"220_CR2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","volume":"94","author":"R Etzioni","year":"2002","unstructured":"Etzioni R, Penson DF, Legler JM et al (2002) Overdiagnosis due prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94:981\u2013990","journal-title":"J Natl Cancer Inst"},{"key":"220_CR3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.eururo.2009.02.028","volume":"55","author":"PJ Bastian","year":"2009","unstructured":"Bastian PJ, Carter BH, Bjartell A et al (2009) Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55:1321\u20131332","journal-title":"Eur Urol"},{"key":"220_CR4","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591\u20131597","journal-title":"JAMA"},{"key":"220_CR5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)63946-8","volume":"169","author":"M Han","year":"2003","unstructured":"Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517\u2013523","journal-title":"J Urol"},{"key":"220_CR6","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1373\/clinchem.2008.110668","volume":"54","author":"G Sardena","year":"2008","unstructured":"Sardena G, Dowell B, Diamandis EP (2008) Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 54:1951\u20131960","journal-title":"Clin Chem"},{"key":"220_CR7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/MOU.0b013e32832a08b5","volume":"19","author":"Y Fradet","year":"2009","unstructured":"Fradet Y (2009) Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate specific antigen. Curr Opin Urol 19:243\u2013246","journal-title":"Curr Opin Urol"},{"key":"220_CR8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ucl.2009.11.006","volume":"37","author":"M Fiorentino","year":"2010","unstructured":"Fiorentino M, Capizzi E, Loda M (2010) Biomarkers in prostate cancer: state of the art. Urol Clin N Am 37:131\u2013141","journal-title":"Urol Clin N Am"},{"key":"220_CR9","first-page":"1677","volume":"60","author":"J Xu","year":"2000","unstructured":"Xu J, Stolk JA, Zhang X et al (2000) Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60:1677\u20131682","journal-title":"Cancer Res"},{"key":"220_CR10","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.juro.2008.01.012","volume":"179","author":"J Stewart","year":"2008","unstructured":"Stewart J, Fleshner N, Cole H et al (2008) Prognostic significance of alpha-methyl-Co a racemase among men with high grade PIN in prostate biopsies. J Urol 179:1751\u20131755","journal-title":"J Urol"},{"key":"220_CR11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.20039","volume":"100","author":"SF Shariat","year":"2004","unstructured":"Shariat SF, Lotan Y, Saboorian H et al (2004) Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100:751\u2013757","journal-title":"Cancer"},{"key":"220_CR12","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/S0022-2275(20)31983-0","volume":"41","author":"S Ferdinandusse","year":"2000","unstructured":"Ferdinandusse S, Denis S, IJlst L et al (2000) Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 41:1890\u20131896","journal-title":"J Lipid Res"},{"key":"220_CR13","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jama.287.13.1662","volume":"287","author":"MA Rubin","year":"2002","unstructured":"Rubin MA, Zhou M, Dhanasekaran SM et al (2002) Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287:1662\u20131670","journal-title":"JAMA"},{"key":"220_CR14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1309\/EJUYUQPEX1MG68MK","volume":"122","author":"Z Jiang","year":"2004","unstructured":"Jiang Z, Woda BA, Wu C et al (2004) Discovery and clinical application of a novel prostate cancer marker \u03b1-methylacyl CoA racemase (P504S). Am J Clin Pathol 122:275\u2013289","journal-title":"Am J Clin Pathol"},{"key":"220_CR15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1471-4914(01)02243-2","volume":"7","author":"DC Altieri","year":"2001","unstructured":"Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542\u2013547","journal-title":"Trends Mol Med"},{"key":"220_CR16","first-page":"43","volume":"152","author":"C Adida","year":"1998","unstructured":"Adida C, Crotty PL, McGrath J et al (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43\u201349","journal-title":"Am J Pathol"},{"key":"220_CR17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","volume":"3","author":"G Ambrosini","year":"1997","unstructured":"Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917\u2013921","journal-title":"Nat Med"},{"key":"220_CR18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/01.ju.0000120317.88372.03","volume":"171","author":"H Kishi","year":"2004","unstructured":"Kishi H, Igawa M, Kikuno N et al (2004) Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171:1855\u20131860","journal-title":"J Urol"},{"key":"220_CR19","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/00000478-200111000-00007","volume":"25","author":"Z Jiang","year":"2001","unstructured":"Jiang Z, Woda BA, Rock KL et al (2001) P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25:1397\u20131404","journal-title":"Am J Surg Pathol"},{"key":"220_CR20","first-page":"93","volume":"9","author":"JC Presti","year":"2007","unstructured":"Presti JC (2007) Prostate biopsy: current status and limitations. Rev Urol 9:93\u201398","journal-title":"Rev Urol"},{"key":"220_CR21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method. Methods 25:402\u2013408","journal-title":"Methods"},{"key":"220_CR22","first-page":"2220","volume":"62","author":"J Luo","year":"2002","unstructured":"Luo J, Zha S, Gage WR et al (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62:2220\u20132226","journal-title":"Cancer Res"},{"key":"220_CR23","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/00000478-200212000-00006","volume":"26","author":"R Beach","year":"2002","unstructured":"Beach R, Gown AM, De Peralta-Venturina MN et al (2002) P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 26:1588\u20131596","journal-title":"Am J Surg Pathol"},{"key":"220_CR24","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/01.ju.0000137659.53129.14","volume":"172","author":"CG Rogers","year":"2004","unstructured":"Rogers CG, Yan G, Zha S et al (2004) Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 172:1501\u20131503","journal-title":"J Urol"},{"key":"220_CR25","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.ju.0000133560.87118.4d","volume":"172","author":"PJ Zielie","year":"2004","unstructured":"Zielie PJ, Mobley JA, Ebb RG et al (2004) A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. J Urol 172:1130\u20131133","journal-title":"J Urol"},{"key":"220_CR26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF03256217","volume":"10","author":"BK Zehentner","year":"2006","unstructured":"Zehentner BK, Secrist H, Zhang X et al (2006) Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients. Mol Diagn Ther 10:397\u2013403","journal-title":"Mol Diagn Ther"},{"key":"220_CR27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0002-9440(10)64244-7","volume":"161","author":"R Kuefer","year":"2002","unstructured":"Kuefer R, Varambally S, Zhou M et al (2002) Alphamethylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumour differentiation. Am J Pathol 161:841\u2013848","journal-title":"Am J Pathol"},{"key":"220_CR28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cdp.2006.07.010","volume":"30","author":"M Schostak","year":"2006","unstructured":"Schostak M, Miller K, Krause H et al (2006) Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions. Cancer Detect Prev 30:449\u2013454","journal-title":"Cancer Detect Prev"},{"key":"220_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pros.1076","volume":"48","author":"N Xing","year":"2001","unstructured":"Xing N, Qian J, Bostwick D et al (2001) Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48:7\u201315","journal-title":"Prostate"},{"key":"220_CR30","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1097\/01.ju.0000176459.79180.d1","volume":"174","author":"SF Shariat","year":"2005","unstructured":"Shariat SF, Ashfaq R, Roehrborn CG et al (2005) Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 174:2046\u20132050","journal-title":"J Urol"},{"key":"220_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5858\/2004-128-39-SABEIP","volume":"128","author":"P Kaur","year":"2004","unstructured":"Kaur P, Kallakury BS, Sheehan CE et al (2004) Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 128:39\u201343","journal-title":"Arch Pathol Lab Med"},{"key":"220_CR32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1590\/S1677-55382008000500004","volume":"34","author":"L Nesrallah","year":"2008","unstructured":"Nesrallah L, Nesrallah A, Antunes AA et al (2008) The role of extended prostate biopsy on prostate cancer detection rate: a study performed on the bench. Int Braz J Urol 34:563\u2013570","journal-title":"Int Braz J Urol"},{"key":"220_CR33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.urolonc.2006.11.008","volume":"26","author":"R Etzioni","year":"2008","unstructured":"Etzioni R (2008) Statistical issues in the evaluation of screening and early detection modalities. Urol Oncol 26:308\u2013315","journal-title":"Urol Oncol"},{"key":"220_CR34","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/01.ju.0000139993.51181.5d","volume":"172","author":"TA Stamey","year":"2004","unstructured":"Stamey TA, Caldwell M, McNeal JE et al (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20\u00a0years? J Urol 172:1297\u20131301","journal-title":"J Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-012-0220-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-012-0220-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-012-0220-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T13:40:02Z","timestamp":1643204402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-012-0220-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,21]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1007\/s11255-012-0220-2","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,21]]}}}